SMA Peg denied as non-formulary by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied This Claim — and Why It's Appealable

A non-formulary denial for a pegylated SMA therapy means the drug is not on Anthem's standard formulary tier structure for the patient's plan, resulting in a denial or a cost-share level that may be prohibitive. For rare diseases like SMA, formulary placement frequently lags FDA approval — and plans are required to have an exceptions process precisely for situations where no formulary alternative is clinically appropriate. Formulary exception appeals in rare-disease settings succeed at a meaningful rate, especially when the prescribing physician documents the absence of a comparable formulary alternative.

## Your Federal Appeal Rights

ACA §2719 and, for grandfathered or ERISA plans, ERISA §503 give you the right to a full internal appeal and independent external review. The external review window is generally four months from the denial date. Importantly, ACA-compliant plans are required to offer an exceptions process for non-formulary drugs when a formulary alternative is contraindicated or clinically inappropriate — request a formulary exception simultaneously with or before the formal appeal. Expedited review is available if delay creates serious clinical risk.

## Concrete Appeal Steps

1. Request Anthem's formulary exception process — this is often a faster route than a full appeal and can be initiated by the prescribing physician directly. 2. Identify all formulary alternatives for SMA on the plan — the prescribing physician must explain in writing why each formulary alternative is clinically inappropriate for this specific patient. 3. File the formulary exception request and/or Level 1 internal appeal with a complete clinical package. 4. If denied, escalate to Level 2 and then external review; IROs evaluate whether the plan's refusal to approve a non-formulary exception was clinically justified. 5. Check state law: some states have enhanced protections requiring formulary exceptions for FDA-approved therapies with no appropriate alternative.

## Documentation to Gather

• Diagnosis confirmation: Genetic test confirming SMA type and molecular subtype relevant to drug selection.
• Formulary alternative analysis: A prescriber letter reviewing each formulary SMA therapy and explaining — with chart-specific clinical reasoning — why each is not appropriate for this patient (different mechanism, contraindication, prior failure, or inapplicable patient subgroup).
• FDA labeling for the requested drug: Confirms the approved indication and the patient population the prescriber is targeting, demonstrating alignment between the prescription and the label.
• Prescriber medical-necessity letter: Individualized letter citing the applicable guideline organization (e.g., AAN or relevant neuromuscular society guidelines) and explaining why this specific agent is medically necessary when formulary alternatives are not appropriate.
• Clinical severity and trajectory: Chart documentation supporting urgency and the clinical cost of substitution or delay.

## Criteria-Mapping Structure

For formulary exception appeals, the key table has three columns: the formulary alternative Anthem might suggest, the clinical reason that alternative is inappropriate for this patient (with chart citation), and the source document. This directly addresses the core question every reviewer asks: "Why can't the patient use what's on the formulary?"